Skip to Main Content

They may be unparalleled lifesavers. Or they may be keeping lifesaving drugs off the market.

For more than three hours on Monday, FDA officials heard dramatically different forecasts for the future of fecal matter transplants, a relatively new therapy that is mostly used to treat recurrent Clostridium difficile infections. The meeting happened less than a week after a paper in the New England Journal of Medicine revealed new details about the first-ever death associated with the procedure.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!